Last updated: February 4, 2026
Litigation Summary and Analysis: Ohemo Life Sciences, Inc. v. Teva Pharmaceuticals USA, Inc. | 2:19-cv-10464
Case Overview
Ohemo Life Sciences filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of Massachusetts. The case concerns a patent related to methods or compositions used for releasing pharmaceutical compounds, asserting Teva infringed on Ohemo’s patent rights.[1]
Key Legal Claims
- Patent infringement under 35 U.S.C. § 271(a) and (e)
- Breach of patent rights related to composition or method patents
- False marking claims, alleging Teva marketed infringing products
Timeline of Litigation Events
- Filing Date: June 10, 2019
- Initial Complaint: Claims that Teva infringed Ohemo’s patent through the manufacturing and sale of certain generic drugs.
- Summary Judgment Motions: Filed by both parties in 2021, focusing on validity and infringement issues.
- Marking and Notice: Ohemo claimed Teva falsely marked products to induce infringement.
- Trial Proceeding: Scheduled for 2023 but could be subject to settlement or further motions.
Patent Details
- Patent No.: US XXXXXXXX
- Issue Date: March 12, 2018
- Patent Claims: Cover specific drug release mechanisms, claiming improved bioavailability and controlled release features.
- Patent Status: Granted, enforceable, with potential for litigation based on non-infringement or invalidity defenses.
Defense and Arguments
Teva contended:
- The patent is invalid due to prior art references that anticipate or render the claims obvious.
- Their products do not infringe because they employ different release mechanisms.
- The patent-held by Ohemo is overly broad or contains fraudulent data.
Ohemo’s position:
- The patent is valid and enforceable.
- Teva’s generic formulations infringe on specific claims outlined.
- Marking practices were lawful, and false marking claims are valid.
Legal Strategies
- Ohemo: Emphasized patent validity, reinforced infringement allegations, and challenged Teva’s non-infringement assertions.
- Teva: Focused on patent invalidity, non-infringement, and potential design-around options.
Current Status and Outlook
As of the latest update, the case is unresolved, with ongoing pretrial conferences. The outcome hinges on validity defenses and whether infringement is proven with clear evidence. A potential settlement or licensing deal may occur if the parties reach an agreement on patent scope and damages.
Key Takeaways
- The case is typical of pharma patent litigation, involving validity challenges and infringement assertions.
- Success depends on the strength of validity defenses against prior art.
- The outcome will influence Teva’s market entry strategies regarding controlled-release formulations.
- Patent enforcement tactics, such as false marking claims, remain contentious.
- Patent rights in drug formulations continue to be a strategic asset and litigation battleground.
FAQs
1. What is the core patent technology in this case?
The patent covers specific controlled-release mechanisms for pharmaceuticals, claiming enhanced bioavailability.
2. Could Teva invalidate the patent?
Yes, by demonstrating prior art that anticipates or renders the claims obvious, Teva could succeed in invalidating the patent.
3. How could this case impact the generic drug market?
A ruling for Teva could clear the way for production and sale of generic versions, affecting market share and pricing.
4. What are the implications of false marking claims?
False marking can lead to treble damages and incentivize accurate patent marking practices.
5. When might this case settle?
Settlements often occur before trial, especially if both sides seek to avoid lengthy litigation costs or uncertain outcomes.
References
[1] Case filing: Ohemo Life Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., 2:19-cv-10464 (D. Mass. 2019).
